1. Deals Analysis
March 24, 2021updated 15 Mar 2022 9:18am

Consumer industry cross border M&A deals total $2.3bn globally in February 2021

Total consumer industry cross border M&A deals worth $2.3bn were announced globally in February 2021, led by The Estee Lauder Companies’ $1bn acquisition of DECIEM, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

The value marked a decrease of 67.9% over the previous month of $7.16bn and a drop of 47.6% when compared with the last 12-month average, which stood at $4.39bn.

Comparing cross border M&A deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $1.03bn. At the country level, the Canada topped the list in terms of deal value at $1000m.

In terms of volumes, Europe emerged as the top region for consumer industry cross border M&A deals globally, followed by Asia-Pacific and then North America.

The top country in terms of cross border M&A deals activity in February 2021 was the US with nine deals, followed by the UK with six and Australia with six.

In 2021, as of February, consumer cross border M&A deals worth $9.46bn were announced globally, marking an increase of 7.3% year on year.

consumer industry cross border M&A deals in February 2021: Top deals

The top five cross border M&A deals accounted for 90.5% of the overall value during February 2021.

The combined value of the top five consumer cross border M&A deals stood at $2.08bn, against the overall value of $2.3bn recorded for the month.

The top five consumer industry cross border M&A deals of February 2021 tracked by GlobalData were:

1) The Estee Lauder Companies’ $1bn acquisition of DECIEM

2) The $468.8m acquisition of Asaleo Care by Essity

3) Greystar Real Estate Partners’ $403.57m asset transaction with KKRInc

4) The $106.33m asset transaction with Biosearch by Kerry Group

5) Karo Pharma’s acquisition of Teva Pharmaceutical Industries for $101.22m.